CRDL — Cardiol Therapeutics Balance Sheet
0.000.00%
- CA$123.09m
- CA$92.67m
Annual balance sheet for Cardiol Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 14 | 83.9 | 59.5 | 34.9 | 30.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.22 | 0.407 | 0.48 | 0.28 | 0.362 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 14.9 | 87.1 | 61.4 | 36.2 | 31.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.48 | 0.356 | 0.296 | 0.337 | 0.196 |
Net Intangible Assets | |||||
Total Assets | 15.9 | 87.9 | 62 | 36.7 | 31.9 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.52 | 11.6 | 9.8 | 8.3 | 7.01 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 2.62 | 11.6 | 9.83 | 8.45 | 7.14 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 13.3 | 76.2 | 52.2 | 28.2 | 24.7 |
Total Liabilities & Shareholders' Equity | 15.9 | 87.9 | 62 | 36.7 | 31.9 |
Total Common Shares Outstanding |